Actively Recruiting

Age: 1Year +
All Genders
ID06078098

Multicenter, Nationwide, Observational, Retrospective and Prospective Study to Develop an Autoimmune Hepatitis Patient Database and Biological Sample Storage

Led by University of Milano Bicocca · Updated on 2023-10-11

10000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Autoimmune Hepatitis (AIH) is a chronic liver disease characterized by ongoing inflammation that can lead to liver failure and the need for transplantation. Both children and adults are affected, with some patients facing reduced life expectancy despite treatment. This study aims to develop a national registry in Italy to better understand the incidence, prevalence, disease progression, and impact of AIH, as well as to assess safety and long-term effects of new therapies. It is an observational, multicenter, retrospective and prospective study focusing on patients older than 1 year. The study will enroll approximately 10,000 AIH patients across Italy over a 120-month period, collecting clinical information, laboratory tests, and biological samples. There is no experimental treatment involved; instead, the study gathers data from patients diagnosed according to recent guidelines. Patients will be followed for a minimum of one year to monitor disease course and outcomes. Participants will provide clinical data and biological samples during the study, with ongoing assessments of liver function and disease activity using various blood tests and liver stiffness measurements. Researchers will track biochemical responses, disease relapse, liver complications requiring hospital admission, and other laboratory indicators over the 11-year study duration. This long-term monitoring will help characterize AIH progression and treatment safety in the Italian population.

CONDITIONS

Brief Title

Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage

Who Can Participate

Age: 1Year +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • All Autoimmune Hepatitis patients living in Italy and aged at least 1 year
  • Willing and able to give informed consent prior to any study-specific procedure
  • Diagnosis of Autoimmune Hepatitis according to the most recent published guidelines (EASL)
Not Eligible

You will not qualify if you...

  • Subject unwilling to participate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surveillance

Duration - Up to 10 years

Participants who undergo routine care are observed with clinical information and laboratory investigations collected along with biological samples to monitor disease characteristics and progression.

Regular assessments as part of routine healthcare

Long-term Monitoring

Duration - Minimum 1 year

Participants are followed for at least 1 year to track disease outcomes, safety, and effectiveness of therapies through ongoing data and sample collection.

Follow-up visits as determined by clinical management

Trial Site Locations

Total: 1 location

1

Fondazione IRCCS San Gerardo dei Tintori

Monza, MB, Italy, 20900

Actively Recruiting

Loading map...

Research Team

P

Pietro Invernizzi, MD

A

Alessio Gerussi, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A 12-Month, Open-Label Study Evaluating Safety, Tolerability...

Autoimmune Liver Disease

Actively Recruiting

1 location

Autoimmune Liver Disease Network for Kids (A-LiNK): Using Pa...

Autoimmune Hepatitis

Actively Recruiting

8 locations

Clinical Characteristics and Outcomes of Autoimmune Hepatiti...

Autoimmune Hepatitis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Increased Mortality Risk in Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology.

Rajani Sharma, Elizabeth C Verna, Jonas Söderling...

https://pubmed.ncbi.nlm.nih.gov/33065308

Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases.

Cara L Mack, David Adams, David N Assis...

https://pubmed.ncbi.nlm.nih.gov/31863477

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.

Simon Pape, Romée J A L M Snijders, Tom J G Gevers...

https://pubmed.ncbi.nlm.nih.gov/35066089

Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission.

Nicole M F van Gerven, Bart J Verwer, Birgit I Witte...

https://pubmed.ncbi.nlm.nih.gov/22989569